Tumor vaccine against recurrence of hepatocellular carcinoma

World Journal of Gastroenterology

Volumn 11, Issue 5, 2005, Pages 700-704

  Peng, Bao Gang ^a   Liang, Li Jiang ^a   He, Qiang ^a   Kuang, Ming ^a   Lia, Jia Ming ^a   Lu, Ming De ^a   Huang, Jie Fu ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

HCC vaccine; Hepatocellular carcinoma; Recurrence

Indexed keywords

CANCER VACCINE;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; BLEEDING; BLOOD TRANSFUSION; CANCER SURGERY; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DESQUAMATION; ERYTHEMA; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HEPATITIS; HUMAN; INCIDENCE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER INJURY; LIVER LOBECTOMY; LIVER RESECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PHASE 2 CLINICAL TRIAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; SKIN TOXICITY; TUMOR VOLUME;

EID: 13544272841     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i5.700     Document Type: Article

References (34)

1. Peto J. Cancer epidemiology in the last century and the next decade. Nature 2001; 411: 390-395
2. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-750
3. Schafer DF, Sorrell MF. Hepatocellular carcinoma. Lancet 1999; 353: 1253-1257
4. Zhou XD, Tang ZY, Yang BH, Lin ZY, Ma ZC, Ye SL, Wu ZQ, Fan J, Qin LX, Zheng BH. Experience of 1000 patients who underwent hepatectomy for small hepatocellular carcinoma. Cancer 2001; 91 1479-1486
5. Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: Implications for a strategy of salvage transplantation. Ann Surg 2002; 235: 373-382
6. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002; 35: 519-524
7. Fong Y, Sun RL, Jarnagin W, Blumgart LH. An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg 1999; 229: 790-798
8. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33: 1394-1403
9. Lee WC, Jeng LB, Chen MF. Estimation of prognosis after hepatectomy for hepatocellular carcinoma. Br J Surg 2002; 89: 311-316
10. Vermorken JB, Claessen AM, van Tinteren H, Gall HE, Ezinga R, Meijer S, Scheper RJ, Meijer CJ, Bloemena E, Ransom JH, Hanna MG Jr, Pinedo HM. Active specific immunotherapy for stage II and stage III human colon cancer: A randomised trial. Lancet 1999; 353: 345-350
11. Soiffer R, Lynch T, Mihm M, Jung K, Rhuda C, Schmollinger JC, Hodi FS, Liebster L, Lam P, Mentzer S, Singer S, Tanabe KK, Cosimi AB, Duda R, Sober A, Bhan A, Daley J, Neuberg D, Parry G, Rokovich J, Richards L, Drayer J, Berns A, Clift S, Dranoff G. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci USA 1998; 95: 13141-13146
12. Protti MP, Bellone IA. Immunotherapy: Natural versus synthetic peptides. Immunol Today 1998; 19: 98
13. Gong J, Chen D, Kashiwaba M, Kufe D. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 1997; 3: 558-561
14. Pardoll DM. Cancer vaccines. Nat Med 1998; 4 5 Suppl): 525-531
15. Zhang J, Zhang JK, Zhuo SH, Chen HB. Effect of a cancer vaccine prepared by fusions of hepatocarcinoma cells with dendritic cells. World J Gastroenterol 2001; 7: 690-694
16. Guo Y, Wu M, Chen H, Wang X, Liu G, Li G, Ma J, Sy MS. Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells. Science 1994; 263: 518-520
17. Liu SQ, Saijo K, Todoroki T, Ohno T. Induction of human autologous cytotoxic T lymphocytes on formalin-fixed and paraffin-embedded tumour sections. Nat Med 1995; 1: 267-271
18. Liu SQ, Shiraiwa H, Kawai K, Hayashi H, Akaza H, Kim BS, Oki A, Nishida M, Kubo T, Hashizaki K, Saijo K, Ohno T. Tumor-specific autologous cytotoxic T lymphocytes from tissue section. Nat Med 1996; 2: 1283
19. Kim C, Matsumura M, Saijo K, Ohno T. In vitro induction of HLA-A2402-restricted and carcinoembryonic-antigen-specific cytotoxic T lymphocytes on fixed autologous peripheral blood cells. Cancer Immunol Immunother 1998; 47: 90-96
20. Peng BG, Liu SQ, Kuang M, He Q, Totsuka S, Huang L, Huang J, Lu MD, Liang LJ, Leong KW, Ohno T. Autologous fixed tumor vaccine: A formulation with cytokine-microparticles for protective immunity against recurrence of human hepatocellular carcinoma. Jpn J Cancer Res 2002; 93: 363-368
21. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-214
22. McCune CS, O'Donnell RW, Marquis DM, Sahasrabudhe DM. Renal cell carcinoma treated by vaccines for active specific immunotherapy: Correlation of survival with skin testing by autologous tumor cells. Cancer Immunol Immunother 1990; 32: 62-66
23. Vollmer CM Jr, Eilber FC, Butterfield LH, Ribas A, Dissette VB, Koh A, Montejo LD, Lee MC, Andrews KJ, McBride WH, Glaspy JA, Econowou JS. α-fetoprotein-specific genetic immunotherapy for hepatocellular carcinoma. Cancer Res 1999; 59: 3064-3067
24. Meng WS, Butterfield LH, Ribas A, Dissette VB, Heller JB, Miranda GA, Glaspy JA, McBride WH, Economou JS. α-Feto-protein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination. Cancer Res 2001; 61 8782-8786
25. Nestle FO, Banchereau J, Hart D. Dendritic cells: On the move from bench to bedside. Nat Med 2001; 7: 761-765
26. Homma S, Toda G, Gong J, Kufe D, Ohno T. Preventive antitumor activity against hepatocellular carcinoma (HCC) induced by immunization with fusions of dendritic cells and HCC cells in mice. J Gastroenterol 2001; 36: 764-771
27. Albert ML, Pearce SF, Francisco LM, Sauter B, Roy P, Silverstein RL, Bhardwaj N. Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med 1998; 188: 1359-1368
28. Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: Endogenous activators of dendritic cells. Nat Med 1999; 5: 1249-1255
29. Falo LD Jr, Kovacsovics-Bankowski M, Thompson K, Rock KL. Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity. Nat Med 1995; 1: 649-653
30. Harding CV, Song R. Phagocytic processing of exogenous particulate antigens by macrophages for presentation by class I MHC molecules. J Immunol 1994; 153: 4925-4933
31. Rock KL, Clark K. Analysis of the role of MHC class II presentation in the stimulation of cytotoxic T lymphocytes by antigens targeted into the exogenous antigen-MHC class I presentation pathway. J Immunol 1996; 156: 3721-3726
32. De Bruijn ML, Jackson MR, Peterson PA. Phagocyte-induced antigen-specific activation of unprimed CD8+ T cells in vitro. Eur J Immunol 1995; 25: 1274-1285
33. De Bruijn ML, Peterson PA, Jackson NM. Induction of heat-stable antigen expression by phagocytosis is involved in in vitro activation of unprimed CTL by macrophages. J Immunol 1996; 156: 2686-2692
34. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kast WM, Deleo AB. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1995; 1: 1297-1302